Literature DB >> 26372382

Lysis of HIV-1-infected autologous CD4+ primary T cells by interferon-alpha-activated NK cells requires NKp46 and NKG2D.

Costin Tomescu1, Domenico Mavilio, Luis J Montaner.   

Abstract

OBJECTIVE: Autologous HIV-1-infected CD4 primary T cells (aHIVCD4) have been shown to be largely resistant to natural killer (NK)-cell-mediated lysis because of viral strategies of immune evasion. We have previously shown that a preactivation of NK cells with plasmacytoid dendritic cells can significantly augment lysis of aHIVCD4 through a mechanism dependent on interferon-alpha (IFN-α).
DESIGN: The goal of the present study is to identify the specific NK-activating receptors involved in NK lysis of aHIVCD4 following IFN-α activation.
METHODS: Peripheral blood mononuclear cells (PBMC) were incubated with aHIVCD4 to induce the secretion of endogenous levels of IFN-α and drive NK activation. We then utilized a standard chromium lysis assay to assess the degree of IFN-α-activated lysis of aHIVCD4 in the presence or absence of masking antibodies to a panel of NK-activating receptors and co-receptors.
RESULTS: Direct recognition of HIV-1-infected, but not uninfected, autologous CD4 primary T cells by PBMC induced the secretion IFN-α (median 2280 pg/ml, P < 0.001, n = 9) that, in turn, activated NK cells (P < 0.001, n = 12) and significantly increased their cytolytic potential against aHIVCD4 (P < 0.01, n = 12). The masking of NKp46 (P < 0.01, n = 8) and NKG2D (P < 0.05, n = 8), but not 2B4, NTBA, NKp30 or NKp44, significantly reduced IFN-α-activated lysis of aHIVCD4.
CONCLUSIONS: Taken together, these results demonstrate that endogenous levels of IFN-α secreted by plasmacytoid dendritic cells induce NK cells to lyse aHIVCD4 via the engagement of NKp46 and NKG2D.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26372382      PMCID: PMC4571461          DOI: 10.1097/QAD.0000000000000777

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  54 in total

Review 1.  Role of chemokines in the biology of natural killer cells.

Authors:  Michael J Robertson
Journal:  J Leukoc Biol       Date:  2002-02       Impact factor: 4.962

2.  Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells.

Authors:  Geraldine M O'Connor; Kieran J Guinan; Rodat T Cunningham; Derek Middleton; Peter Parham; Clair M Gardiner
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

Review 3.  Killer cell inhibitory receptors: diversity, specificity, and function.

Authors:  E O Long; D N Burshtyn; W P Clark; M Peruzzi; S Rajagopalan; S Rojo; N Wagtmann; C C Winter
Journal:  Immunol Rev       Date:  1997-02       Impact factor: 12.988

Review 4.  Interleukin 21: a key player in lymphocyte maturation.

Authors:  Stephen L Nutt; Jason Brady; Yoshihiro Hayakawa; Mark J Smyth
Journal:  Crit Rev Immunol       Date:  2004       Impact factor: 2.214

5.  Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.

Authors:  M A Caligiuri; C Murray; M J Robertson; E Wang; K Cochran; C Cameron; P Schow; M E Ross; T R Klumpp; R J Soiffer
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

6.  Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors.

Authors:  Pascale André; Roberta Castriconi; Marion Espéli; Nicolas Anfossi; Tiffany Juarez; Sophie Hue; Holli Conway; François Romagné; Alessandra Dondero; Marina Nanni; Sophie Caillat-Zucman; David H Raulet; Cristina Bottino; Eric Vivier; Alessandro Moretta; Pascale Paul
Journal:  Eur J Immunol       Date:  2004-04       Impact factor: 5.532

Review 7.  Human natural killer cell receptors and co-receptors.

Authors:  R Biassoni; C Cantoni; D Pende; S Sivori; S Parolini; M Vitale; C Bottino; A Moretta
Journal:  Immunol Rev       Date:  2001-06       Impact factor: 12.988

Review 8.  The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases.

Authors:  Thomas Waldmann
Journal:  Arthritis Res       Date:  2002-05-09

9.  Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients.

Authors:  J Chehimi; S E Starr; I Frank; M Rengaraju; S J Jackson; C Llanes; M Kobayashi; B Perussia; D Young; E Nickbarg
Journal:  J Exp Med       Date:  1992-03-01       Impact factor: 14.307

10.  Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals.

Authors:  Manuela Fogli; Domenico Mavilio; Enrico Brunetta; Stefania Varchetta; Khaled Ata; Gregg Roby; Colin Kovacs; Dean Follmann; Daniela Pende; Jeffrey Ward; Edward Barker; Emanuela Marcenaro; Alessandro Moretta; Anthony S Fauci
Journal:  PLoS Pathog       Date:  2008-07-11       Impact factor: 6.823

View more
  29 in total

1.  Impaired Downregulation of NKG2D Ligands by Nef Proteins from Elite Controllers Sensitizes HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity.

Authors:  Nirmin Alsahafi; Jonathan Richard; Jérémie Prévost; Mathieu Coutu; Nathalie Brassard; Matthew S Parsons; Daniel E Kaufmann; Mark Brockman; Andrés Finzi
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

2.  Interferon Alpha Enhances NK Cell Function and the Suppressive Capacity of HIV-Specific CD8+ T Cells.

Authors:  Abena K R Kwaa; Chloe A G Talana; Joel N Blankson
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

Review 3.  Impact of Myeloid Reservoirs in HIV Cure Trials.

Authors:  Brooks I Mitchell; Elizabeth I Laws; Lishomwa C Ndhlovu
Journal:  Curr HIV/AIDS Rep       Date:  2019-04       Impact factor: 5.071

Review 4.  Antibody-dependent cellular cytotoxicity in HIV infection.

Authors:  Donald N Forthal; Andrés Finzi
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

5.  Pegylated Interferon-α-Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy-Treated HIV-1/Hepatitis C Virus-Coinfected Patients.

Authors:  Stéphane Hua; Selena Vigano; Samantha Tse; Ouyang Zhengyu; Sean Harrington; Jordi Negron; Pilar Garcia-Broncano; Giulia Marchetti; Miguel Genebat; Manuel Leal; Salvador Resino; Ezequiel Ruiz-Mateos; Mathias Lichterfeld; Xu G Yu
Journal:  Clin Infect Dis       Date:  2018-06-01       Impact factor: 9.079

6.  Interferon-α alters host glycosylation machinery during treated HIV infection.

Authors:  Leila B Giron; Florent Colomb; Emmanouil Papasavvas; Livio Azzoni; Xiangfan Yin; Matthew Fair; Alitzel Anzurez; Mohammad Damra; Karam Mounzer; Jay R Kostman; Pablo Tebas; Una O'Doherty; Hiroaki Tateno; Qin Liu; Michael R Betts; Luis J Montaner; Mohamed Abdel-Mohsen
Journal:  EBioMedicine       Date:  2020-08-19       Impact factor: 8.143

7.  Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo.

Authors:  Carolina Garrido; Maria Abad-Fernandez; Marina Tuyishime; Justin J Pollara; Guido Ferrari; Natalia Soriano-Sarabia; David M Margolis
Journal:  J Virol       Date:  2018-05-29       Impact factor: 5.103

Review 8.  Natural killer cells in HIV-1 infection and therapy.

Authors:  Joanna Mikulak; Ferdinando Oriolo; Elisa Zaghi; Clara Di Vito; Domenico Mavilio
Journal:  AIDS       Date:  2017-11-13       Impact factor: 4.177

9.  Identification of NK Cell Subpopulations That Differentiate HIV-Infected Subject Cohorts with Diverse Levels of Virus Control.

Authors:  Christopher W Pohlmeyer; Veronica D Gonzalez; Alivelu Irrinki; Ricardo N Ramirez; Li Li; Andrew Mulato; Jeffrey P Murry; Aaron Arvey; Rebecca Hoh; Steven G Deeks; George Kukolj; Tomas Cihlar; Stefan Pflanz; Garry P Nolan; Gundula Min-Oo
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

10.  Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs.

Authors:  Liang Cheng; Jianping Ma; Jingyun Li; Dan Li; Guangming Li; Feng Li; Qing Zhang; Haisheng Yu; Fumihiko Yasui; Chaobaihui Ye; Li-Chung Tsao; Zhiyuan Hu; Lishan Su; Liguo Zhang
Journal:  J Clin Invest       Date:  2016-12-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.